Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

A Randomized, Parallel, Open-label, Multicenter, Positive-controlled, Superiority Phase III Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.

Studieoversikt

Detaljert beskrivelse

This study is a randomized, parallel, open-label, multicenter, positive-controlled, superiority-designed Phase III clinical study evaluating the efficacy and safety of octreotide long-acting injection in patients with acromegaly. The purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in treating acromegaly. Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort. A total of 154 participants are expected to be enrolled. The study will consist of a maximum 4-week screening/Baseline period, followed by 28-week treatment period.

Studietype

Intervensjonell

Registrering (Antatt)

154

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Clinical Trials Information Group officer
  • Telefonnummer: +86311-69085587
  • E-post: ctr-contact@cspc.cn

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Male or female participants aged 18 to 80 years (including boundary values)
  • Diagnosed with acromegaly, currently in the active stage of the disease (for patients who have not undergone pituitary tumor surgery before, MRI shows a pituitary mass, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3; for patients who have undergone pituitary tumor surgery, fasting GH ≥ 2.5 ng/mL and IGF-1 index ≥ 1.3);

Exclusion Criteria:

  • Have received pituitary radiotherapy within the 5 years prior to screening
  • Have undergone major surgery (including pituitary surgery) within 6 months prior to screening or are expected to require surgery (including pituitary surgery) or radiotherapy during the study period
  • Within three months before the screening, participants received drugs such as long-acting lanretide, long-acting octreotide, pervesomone, and cabergoline, or traditional Chinese medicines for treating acromegaly. Receive bromocriptine within one month before screening; Received short-acting octreotide or lanretide short-acting preparations for treatment within 7 days before screening; Or have received any other investigational drug within 30 days before screening or within 5 half-lives (whichever is longer)
  • Previous failure to respond to octreotide or lantreotide monotherapy (defined as: after at least 3 months of treatment with octreotide microspheres ≥30 mg or lantreotide ≥120 mg, or after at least 3 months of treatment with parietide microspheres ≥40 mg, random GH ≥2.5 ng/mL and/or IGF-1 index ≥1.3) or history of intolerance.
  • Participants with obvious visual field defects caused by optic chiasm compression and requiring surgical intervention
  • HbA1c>8.5%

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: SYHX2008
The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 28 weeks.
Eksperimentell: Sandostatin LAR®
The patients will accept Sandostatin LAR@ by intra-muscular administration.A treatment period of 28 weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The proportion of patients with an IGF-1 index ≤ 1.0
Tidsramme: Week 28
insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range
Week 28

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The proportion of patients with fasting GH less than 2.5 ng/mL and IGF-1 index less than or equal to 1.0
Tidsramme: weeks 4、8、12、16、20、24、28
weeks 4、8、12、16、20、24、28
The proportion of patients with GH less than 1.0 ng/mL and IGF-1 index less than or equal to 1.0
Tidsramme: weeks 4、8、12、16、20、24、28
weeks 4、8、12、16、20、24、28
The proportion of patients with fasting GH < 1.0 ng/mL
Tidsramme: Weeks 4、8、12、16、20、24、28
Weeks 4、8、12、16、20、24、28
The proportion of patients with fasting GH<2.5 ng/mL
Tidsramme: Weeks 4、8、12、16、20、24、28
Weeks 4、8、12、16、20、24、28
The proportion of patients with an IGF-1 index ≤ 1.0
Tidsramme: Weeks 4、8、12、16、20、24
insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range
Weeks 4、8、12、16、20、24
The rate of change in the volume of the pituitary tumor from the baseline
Tidsramme: Weeks 28
Weeks 28
The change in the total PASQ score from the baseline
Tidsramme: Weeks 12、28
Evaluation of effect on was assessed using Patient Assessed Acromegaly Symptom Question ( PASQ ), an acromegaly-specific quality of life instrument.
Weeks 12、28
The change in the total AcroQoL score from the baseline
Tidsramme: Weeks 12、28
Evaluation of effect was assessed using Acromegaly Quality of Life Questionnaire(AcroQoL), an acromegaly-specific quality of life instrument.
Weeks 12、28
The proportion of patients with fasting GH decreased by ≥50% compared to the baseline
Tidsramme: Weeks 4、8、12、16、20、24、28
Weeks 4、8、12、16、20、24、28
The proportion of patients whose IGF-1 index decreased by ≥50% compared with the baseline
Tidsramme: Weeks 4、8、12、16、20、24、28
Weeks 4、8、12、16、20、24、28
Percentage changes in fasting GH from baseline
Tidsramme: Weeks 4、8、12、16、20、24、28
Weeks 4、8、12、16、20、24、28
Percentage changes in IGF-1 from baseline
Tidsramme: Weeks 4、8、12、16、20、24、28
Weeks 4、8、12、16、20、24、28
Incidence of adverse events (AE)
Tidsramme: From the signing of informed consent up to 28 Weeks after the first dose
Proportion of subjects with adverse events (AEs) within Weeks 28
From the signing of informed consent up to 28 Weeks after the first dose
The concentration of octreotide
Tidsramme: From the signing of informed consent up to 28 Weeks afterthe first dose
The concentration of octreotide in the plasma of patients with acromegaly after administration of SYHX2008 injection and Sandostatin LAR®
From the signing of informed consent up to 28 Weeks afterthe first dose

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

31. mai 2026

Primær fullføring (Antatt)

31. juli 2029

Studiet fullført (Antatt)

30. desember 2029

Datoer for studieregistrering

Først innsendt

29. mai 2026

Først innsendt som oppfylte QC-kriteriene

29. mai 2026

Først lagt ut (Faktiske)

3. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SYHX2008-006

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere